Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.

Rich, P; Bourcier, M; Sofen, H; Fakharzadeh, S; Wasfi, Y; Wang, Y; Kerkmann, U; Ghislain, P-D; Poulin, Y

Rich, P; Bourcier, M; Sofen, H; Fakharzadeh, S; Wasfi, Y; Wang, Y; Kerkmann, U; Ghislain, P-D; Poulin, Y.

Affiliation

Rich P; Dermatology and Clinical Research, Oregon Health Science University, 2565 NW Lovejoy Street, Suite 200, Portland, OR, 97210, U.S.A.

Br J Dermatol ; 170(2): 398-407, 2014 Feb.

Article in En | MEDLINE | ID: mdl-24117389

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; Dermatologic Agents/administration & dosage; Nail Diseases/drug therapy; Psoriasis/drug therapy; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Ustekinumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents / Antibodies, Monoclonal, Humanized / Nail Diseases Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2014 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google